Pharmacokinetic-rate images of indocyanine green for breast tumors using near-infrared optical methods

Department of Electrical, Computer, and Systems Engineering, Rensselaer Polytechnic Institute, Troy, NY, USA.
Physics in Medicine and Biology (Impact Factor: 2.76). 03/2008; 53(4):837-59. DOI: 10.1088/0031-9155/53/4/002
Source: PubMed


In this paper, we develop a method of forming pharmacokinetic-rate images of indocyanine green (ICG) and apply our method to in vivo data obtained from three patients with breast tumors. To form pharmacokinetic-rate images, we first obtain a sequence of ICG concentration images using the differential diffuse optical tomography technique. We next employ a two-compartment model composed of plasma, and extracellular-extravascular space (EES), and estimate the pharmacokinetic rates and concentrations in each compartment using the extended Kalman filtering framework. The pharmacokinetic-rate images of the three patient show that the rates from the tumor region and outside the tumor region are statistically different. Additionally, the ICG concentrations in plasma, and the EES compartments are higher around the tumor region agreeing with the hypothesis that around the tumor region ICG may act as a diffusible extravascular flow in compromised capillary of cancer vessels. Our study indicates that the pharmacokinetic-rate images may provide superior information than single set of pharmacokinetic rates estimated from the entire breast tissue for breast cancer diagnosis.

Download full-text


Available from: Xavier Intes,
    • "In the conventional method of DFMT, the distributions of fluorophore concentration at different time points are reconstructed first and then curve-fitting or pharmacokinetic analysis technique can be applied to the distributions to obtain the time courses of fluorophore concentration [13]–[17] or pharmacokinetic-rate images [18]. The reconstruction method requires that the fluorophore concentrations are stationary during the data collection period. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dynamic fluorescence molecular tomography (DFMT) is a potential approach for drug delivery, tumor detection, diagnosis and staging. The purpose of DFMT is to quantify the changes of fluorescent agents in the bodies, which offer important information about the underlying physiological processes. However, the conventional method requires that the fluorophore concentrations to be reconstructed are stationary during the data collection period. As thus, it cannot offer the dynamic information of fluorophore concentration variation within the data collection period. In this paper, a method is proposed to reconstruct the fluorophore concentration variation instead of the fluorophore concentration through a linear approximation. The fluorophore concentration variation rate is introduced by the linear approximation as a new unknown term to be reconstructed and is used to obtain the time courses of fluorophore concentration. Simulation and phantom studies are performed to validate the proposed method. The results show that the method is able to reconstruct the fluorophore concentration variation rates and the time courses of fluorophore concentration with relative errors less than 0.0218.
    IEEE transactions on bio-medical engineering 07/2014; 62(1). DOI:10.1109/TBME.2014.2342293 · 2.35 Impact Factor
  • Source
    • "As a consequence of i)–iv), fluorescence dynamics in humans have been studied only in body-parts. The dynamic absorption and fluorescence contrast of the unspecific blood-pool tracer indocyanine green (ICG) [7], [8] have been shown to detect signs of rheumatoid arthritis [9], hemodynamic changes in diabetic feet [10], sentinel lymph nodes and lymph drainage [11]–[15], and breast cancer [16]–[20]. Feasibility studies in the brain have demonstrated that even deep tissue can be targeted [21]–[24]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dynamic near-infrared fluorescence (DNIF) whole-body imaging of small animals has become a popular tool in experimental biomedical research. In humans, however, the field of view has been limited to body parts, such as rheumatoid hands, diabetic feet or sentinel lymph nodes. Here we present a new whole-body DNIF-system suitable for adult subjects. We explored whether this system (i) allows dynamic whole-body fluorescence imaging and (ii) can detect modulations in skin perfusion. The non-specific fluorescent probe indocyanine green (ICG) was injected intravenously into two subjects, and fluorescence images were obtained at 5 Hz. The in- and out-flow kinetics of ICG have been shown to correlate with tissue perfusion. To validate the system, skin perfusion was modulated by warming and cooling distinct areas on the chest and the abdomen. Movies of fluorescence images show a bolus passage first in the face, then in the chest, abdomen and finally in the periphery (∼10, 15, 20 and 30 seconds, respectively). When skin perfusion is augmented by warming, bolus arrives about 5 seconds earlier than when the skin is cooled and perfusion decreased. Calculating bolus arrival times and spatial fitting of basis time courses extracted from different regions of interest allowed a mapping of local differences in subcutaneous skin perfusion. This experiment is the first to demonstrate the feasibility of whole-body dynamic fluorescence imaging in humans. Since the whole-body approach demonstrates sensitivity to circumscribed alterations in skinperfusion, it may be used to target autonomous changes in polyneuropathy and to screen for peripheral vascular diseases.
    PLoS ONE 12/2013; 8(12):e83749. DOI:10.1371/journal.pone.0083749 · 3.23 Impact Factor
  • Source
    • "Therefore, pharmacokinetics of ICG has the potential to provide new tools for tumor detection, diagnosis and staging. Pharmacokinetic-rate images of ICG for breast tumors using near-infrared optical methods have been also investigated for breast cancer treatment with ICG-PDT [8]. Photothermal effects on murine mammary tumors using ICG and an 808-nm diode laser effectively caused tumor cell destruction and enhanced ablation and eradicatation of tumor tissue [9]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Photodynamic therapy (PDT) is used for the treatment of many types of predominantly epithelial cancers. Photosensitizer is taken up by fast growing tumor cells more actively than by other body cells and is activated by light, generating reactive oxygen species that cause cell death by necrosis or apoptosis. This study aimed to evaluate the efficacy of PDT with indocyanine green (ICG) through the investigation of TP53, HER-2 and TOP2A genes signals as breast cancer gene markers by interphase fluorescence in situ hybridization (nuc-FISH). The photosynthetizer ICG (200μM) was applied to breast cancer cell line MCF-7 cells (adenocarcinoma) in combination with laser irradiation (807nm) exposure for 20min and then incubated for 12, 24 and 48h. Cell viability was evaluated using trypan blue. The signals for nuc-FISH was investigated and counted for probes specific for the genes TP53 (17p13), HER-2 (17q11.2-q12), and TOP2A (17q21-q22), and BAC-probes RP11-746M1 in 17p11.2 and RP11-403E9 in 17q11.2. The cell viability of MCF-7 did not reduced significantly when the cells were treated with ICG (200μM) or exposed to laser irradiation for 20min followed by incubation for 24h. ICG/PDT treatment with laser irradiation exposure for 20min reduced the cell viability after incubating cells for 12, 24 and 48h highly significantly in a time dependent manner. For nuc-FISH analysis, TP53, HER-2, TOP2A, RP11-746M1 and RP11-403E9 signals did not reduce or increase in a significant manner when the cells were treated with ICG or exposed to laser irradiation for 20min then incubated for 24h. PDT enhanced amplification of TP53 signals from nuc ish 17p13(TP53×2) to nuc ish 17p13(TP53×3) or nuc ish 17p13(TP53×4). However, the signals of HER-2 gene, TOP2A gene and BAC probes were reduced highly significantly when MCF-7 cells were treated with PDT with all time intervals. ICG/PDT and laser induced cytotoxic effect in MCF-7 cells. Also, PDT enhanced TP53 gene amplification, and reduced HER-2, TOP2A, and BAC probes RP11-746M1 and RP11-403E9 signals. Therefore ICG/PDT can be used for breast cancer treatment. It has the potential to induce apoptotic effect and reduce HER-2 and TOP2A genes propagation. Further in vivo studies are needed to evaluate ICG/PDT as a promising therapeutic approach for breast cancer.
    Photodiagnosis and photodynamic therapy 05/2013; 10(2):194-202. DOI:10.1016/j.pdpdt.2012.11.006 · 2.01 Impact Factor
Show more